| Name | Title | Contact Details |
|---|
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Icagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
Covance Labs is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.